Table 2.
Single biomarker associations with cancer incidence and cancer death
| Age- and sex-adjusted model | Multivariable model | ||||
|---|---|---|---|---|---|
| Biomarker | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Cancer incidence (n = 841) | GDF15 | 1.38 (1.24–1.53) | <0.0001 * | 1.31 (1.17–1.47) | <0.0001 ** |
| CD40L | 1.11 (1.03–1.19) | 0.004 | 1.09 (1.02–1.18) | 0.01 | |
| NCAM | 0.90 (0.84–0.97) | 0.005 | 0.94 (0.87–1.02) | 0.12 | |
| GRN | 1.10 (1.02–1.18) | 0.01 | 1.08 (1.01–1.16) | 0.03 | |
| UCMGP | 1.11 (1.02–1.20) | 0.01 | 1.10 (1.01–1.19) | 0.03 | |
| CRP | 1.10 (1.02–1.19) | 0.01 | 1.07 (0.98–1.16) | 0.14 | |
| sICAM1 | 1.09 (1.02–1.17) | 0.02 | 1.05 (0.97–1.13) | 0.23 | |
| TIMP1 | 1.09 (1.01–1.19) | 0.04 | 1.08 (0.99–1.18) | 0.08 | |
| sRAGE | 0.93 (0.87–1.00) | 0.04 | 0.96 (0.89–1.03) | 0.26 | |
| Osteocalcin | 0.93 (0.86–1.00) | 0.04 | 0.95 (0.88–1.02) | 0.14 | |
| MCP1 | 1.08 (1.00–1.16) | 0.047 | 1.06 (0.98–1.14) | 0.14 | |
| Cancer death (n = 221) | GDF15 | 2.58 (2.10–3.15) | <0.0001* | 2.15 (1.72–2.70) | <0.0001 *** |
| SDF1 | 0.71 (0.62–0.82) | <0.0001* | 0.75 (0.65–0.86) | <0.0001 **** | |
| sICAM1 | 1.34 (1.16–1.55) | <0.0001* | 1.21 (1.05–1.41) | 0.01 | |
| MMP9 | 1.33 (1.14–1.54) | <0.0001* | 1.17 (1.01–1.35) | 0.04 | |
| TIMP1 | 1.39 (1.17–1.65) | 0.0002* | 1.31 (1.10–1.56) | 0.002 | |
| CRP | 1.28 (1.10–1.49) | 0.001* | 1.19 (1.01–1.40) | 0.04 | |
| MCP1 | 1.25 (1.08–1.44) | 0.003* | 1.18 (1.02–1.36) | 0.03 | |
| CLEC3B | 0.81 (0.70–0.93) | 0.003* | 0.82 (0.71–0.95) | 0.01 | |
| MMP8 | 1.23 (1.07–1.41) | 0.004* | 1.17 (1.02–1.35) | 0.03 | |
| GP5 | 0.81 (0.71–0.94) | 0.004* | 0.86 (0.75–0.99) | 0.04 | |
| GRN | 1.21 (1.06–1.39) | 0.006* | 1.17 (1.02–1.34) | 0.03 | |
| clusterin | 0.80 (0.68–0.95) | 0.01 | 0.82 (0.69–0.97) | 0.02 | |
| PAI1 | 1.21 (1.04–1.40) | 0.01 | 1.07 (0.91–1.26) | 0.04 | |
| MPO | 1.18 (1.03–1.35) | 0.01 | 1.13 (0.99–1.30) | 0.07 | |
| ADM | 1.23 (1.04–1.47) | 0.02 | 1.11 (0.92–1.34) | 0.28 | |
| LPA | 0.85 (0.74–0.97) | 0.02 | 0.87 (0.76–1.00) | 0.06 | |
| KLKB1 | 0.84 (0.73–0.98) | 0.02 | 0.84 (0.72–0.98) | 0.02 | |
| IGFBP2 | 1.18 (1.02–1.37) | 0.03 | 1.23 (1.04–1.44) | 0.01 | |
| IGF1 | 0.84 (0.72–0.98) | 0.03 | 0.90 (0.77–1.04) | 0.16 | |
| CD14 | 1.17 (1.02–1.35) | 0.03 | 1.08 (0.93–1.25) | 0.33 | |
| GMP_140 | 1.17 (1.01–1.34) | 0.03 | 1.08 (0.94–1.25 | 0.27 | |
| PMP2 | 0.86 (0.75–0.99) | 0.04 | 0.89 (0.77–1.02) | 0.09 | |
| sRAGE | 0.87 (0.76–0.99) | 0.04 | 0.93 (0.81–1.06) | 0.27 | |
| NCAM | 0.87 (0.75–1.00) | 0.05 | 0.96 (0.83–1.11) | 0.57 | |
Multivariable model adjusted for age, sex, BMI, systolic blood pressure, hypertension treatment, diabetes mellitus, smoking, alcohol use, and aspirin use. Displayed raw P-values <0.05 are suggestive of association between biomarker and cancer incidence. Bolded rows denote biomarkers with a significant false discovery rate Q-value <0.05 in age- and sex-adjusted models as well as multivariable models.
*
Denotes Q-value <0.05.
**
Q = 0.0002.
***
Q < 0.0001.
****
Q = 0.002.